141 related articles for article (PubMed ID: 7468294)
1. Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. Efficacy, dosage schedule and plasma levels. An open multicenter study.
Deberdt R; Elens P; Berghmans W; Heykants J; Woestenborghs R; Driesens F; Reyntjens A; van Wijngaarden I
Acta Psychiatr Scand; 1980 Oct; 62(4):356-63. PubMed ID: 7468294
[TBL] [Abstract][Full Text] [Related]
2. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
Roose K
Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
[TBL] [Abstract][Full Text] [Related]
3. A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence.
Vasavan Nair NP; Suranyi-Cadotte B; Schwartz G; Thavundayil JX; Achim A; Lizondo E; Nayak R
J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):30S-37S. PubMed ID: 3514689
[TBL] [Abstract][Full Text] [Related]
4. [Haloperidol decanoate. Results of an open-ended multicentric study in chronic psychotic states].
Lemperiere T; Ropert R; Leger JM; Alexandre JY; Clerc G; Darondel A; Delaunay J; Delteil P; Malauzat D; Raynaud J
Encephale; 1984; 10(5):217-22. PubMed ID: 6519017
[TBL] [Abstract][Full Text] [Related]
5. A loading-dose strategy for converting from oral to depot haloperidol.
Ereshefsky L; Toney G; Saklad SR; Anderson C; Seidel D
Hosp Community Psychiatry; 1993 Dec; 44(12):1155-61. PubMed ID: 7907570
[TBL] [Abstract][Full Text] [Related]
6. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administration.
De Cuyper H; Bollen J; van Praag HM; Verstraeten D
Br J Psychiatry; 1986 May; 148():560-6. PubMed ID: 2877701
[TBL] [Abstract][Full Text] [Related]
8. 12-month study of haloperidol decanoate in chronic schizophrenic patients.
Gelders YG; Reyntijens AJ; Ash CW; Aerts TJ
Int Pharmacopsychiatry; 1982; 17(4):247-54. PubMed ID: 7185769
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of the efficacy of haloperidol decanoate].
Alvarez JV; Li Gambi M
Acta Psiquiatr Psicol Am Lat; 1986 Sep; 32(3):233-6. PubMed ID: 2884807
[TBL] [Abstract][Full Text] [Related]
10. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
Kissling W; Möller HJ; Walter K; Wittmann B; Krueger R; Trenk D
Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacokinetic of haloperidol decanoate in psychotic patients (author's transl)].
Parent M; Toussaint C; Driesens F; Gelders Y
Acta Psychiatr Belg; 1981; 81(4):399-406. PubMed ID: 7331843
[No Abstract] [Full Text] [Related]
12. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
13. Influence of route of administration on haloperidol plasma levels in psychotic patients.
Bianchetti G; Zarifian E; Poirier-Littre MF; Morselli PL; Deniker P
Int J Clin Pharmacol Ther Toxicol; 1980 Jul; 18(7):324-7. PubMed ID: 7429678
[TBL] [Abstract][Full Text] [Related]
14. Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.
McKane JP; Robinson AD; Wiles DH; McCreadie RG; Stirling GS
Br J Psychiatry; 1987 Sep; 151():333-6. PubMed ID: 3322467
[TBL] [Abstract][Full Text] [Related]
15. RBC and plasma levels of haloperidol and clinical response in schizophrenia.
Smith RC; Vroulis G; Shvartsburd A; Allen R; Lewis N; Schoolar JC; Chojnacki M; Johnson R
Am J Psychiatry; 1982 Aug; 139(8):1054-6. PubMed ID: 7091432
[TBL] [Abstract][Full Text] [Related]
16. Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis.
Beresford R; Ward A
Drugs; 1987 Jan; 33(1):31-49. PubMed ID: 3545764
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of haloperidol decanoate. A 2-year follow-up.
Reyntigens AJ; Heykants JJ; Woestenborghs RJ; Gelders YG; Aerts TJ
Int Pharmacopsychiatry; 1982; 17(4):238-46. PubMed ID: 7185768
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology, pharmacokinetics and clinical development of haloperidol decanoate.
Gelders YG
Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():1-11. PubMed ID: 3559159
[TBL] [Abstract][Full Text] [Related]
19. Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder.
Volavka J; Cooper TB; Czobor P; Meisner M
Arch Gen Psychiatry; 1995 Oct; 52(10):837-45. PubMed ID: 7575103
[TBL] [Abstract][Full Text] [Related]
20. Tolerance and serum levels of haloperidol during parenteral and oral haloperidol treatment in geriatric patients.
Viukari M; Salo H; Lamminsivu U; Gordin A
Acta Psychiatr Scand; 1982 Apr; 65(4):301-8. PubMed ID: 7080851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
